Synapse - Works

Results (4640)

Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study

Meeting Abstract

Freemantle, N.; Abou-Alfa, G. K.; Cheng, A. L.; Kelley, R. K.; Valcheva, V.; Benzaghou, F.; Mollon, P.
Annals of Oncology (2019)

Fulltext@MSK | Save

GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2(+)/HER2(-) locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Meeting Abstract

Shah, M.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; Shitara, K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; Borgman-Hagey, A. E.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

Meeting Abstract

Hammel, P.; Kindler, H. L.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt)

Meeting Abstract

Rousseau, B. J. C.; Cohen, J.; Calderaro, J.; Dupuy, A.; Bourgoin, R.; Tournigand, C.; Baumgaertner, I.; Ropert, S.; Thirot Bidault, A.; Klotz, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

Meeting Abstract

Strickler, J. H.; Zemla, T.; Ou, F. S.; Cercek, A.; Wu, C.; Sanchez, F. A.; Hubbard, J.; Jaszewski, B.; Bandel, L.; Schweitzer, B.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Meeting Abstract

Tempero, M. A.; Reni, M.; Riess, H.; O'Reilly, E. M.; Krishnamurthi, S.; Österlund, P.; Ales-Diaz, I. C.; Milella, M.; Siena, S.; Tabernero, J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

Meeting Abstract

Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Meyer, T.; Kelley, R. K.; Mangeshkar, M.; Cheng, A. L.; El-Khoueiry, A. B.; Abou-Alfa, G. K.
Annals of Oncology (2019)

Fulltext@MSK | Save

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

Meeting Abstract

Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save